Abstract
Objective: To evaluate the effectiveness of gonadotropin-releasing hormone agonists (GnRH-a) with or without coadministration of tibolone in women with menstrual cycle-related irritable bowel syndrome (IBS). Design: Prospective, randomized, placebo-controlled clinical trial. Setting: Universities of Catanzaro and Naples. Patient(s): One hundred twenty young premenopausal women with menstrual cycle-related IBS (Rome II criteria). Intervention(s): Administration of leuprolide acetate depot (LAD, 11.25 mg IM/3 months) plus tibolone (group A), LAD plus placebo tablets (group B), and injection of a placebo solution plus placebo tablets (group C). Main Outcome Measure(s): Severity of bowel symptoms or signs of IBS and quality of life (QoL), at baseline and after 6 months of treatment. Result(s): In all groups, the mean scores for each symptom or sign of IBS and for QoL were significantly improved after treatment. A significant difference was observed between group C and groups A and B. No difference between these last groups was detected in symptoms or signs of IBS. The QoL scores were significantly higher in group A than in group B. Conclusion(s): Gondotropin-releasing hormone agonist administration is effective in women with menstrual cycle-related IBS. The addition of tibolone does not reduce effectiveness compared with agonist alone and increases QoL.
| Original language | English |
|---|---|
| Pages (from-to) | 1012-1020 |
| Number of pages | 9 |
| Journal | Fertility and Sterility |
| Volume | 83 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - Apr 2005 |
Fingerprint
Keywords
- GnRH analogue
- Irritable bowel syndrome (IBS)
- Menstrual cycle
- Quality of life
- Sex hormones
ASJC Scopus subject areas
- Obstetrics and Gynaecology
Cite this
Leuprolide acetate treatment with and without coadministration of tibolone in premenopausal women with menstrual cycle-related irritable bowel syndrome. / Palomba, Stefano; Orio, Francesco; Manguso, Francesco; Russo, Tiziana; Falbo, Angela; Lombardi, Gaetano; Doldo, Patrizia; Zullo, Fulvio.
In: Fertility and Sterility, Vol. 83, No. 4, 04.2005, p. 1012-1020.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Leuprolide acetate treatment with and without coadministration of tibolone in premenopausal women with menstrual cycle-related irritable bowel syndrome
AU - Palomba, Stefano
AU - Orio, Francesco
AU - Manguso, Francesco
AU - Russo, Tiziana
AU - Falbo, Angela
AU - Lombardi, Gaetano
AU - Doldo, Patrizia
AU - Zullo, Fulvio
PY - 2005/4
Y1 - 2005/4
N2 - Objective: To evaluate the effectiveness of gonadotropin-releasing hormone agonists (GnRH-a) with or without coadministration of tibolone in women with menstrual cycle-related irritable bowel syndrome (IBS). Design: Prospective, randomized, placebo-controlled clinical trial. Setting: Universities of Catanzaro and Naples. Patient(s): One hundred twenty young premenopausal women with menstrual cycle-related IBS (Rome II criteria). Intervention(s): Administration of leuprolide acetate depot (LAD, 11.25 mg IM/3 months) plus tibolone (group A), LAD plus placebo tablets (group B), and injection of a placebo solution plus placebo tablets (group C). Main Outcome Measure(s): Severity of bowel symptoms or signs of IBS and quality of life (QoL), at baseline and after 6 months of treatment. Result(s): In all groups, the mean scores for each symptom or sign of IBS and for QoL were significantly improved after treatment. A significant difference was observed between group C and groups A and B. No difference between these last groups was detected in symptoms or signs of IBS. The QoL scores were significantly higher in group A than in group B. Conclusion(s): Gondotropin-releasing hormone agonist administration is effective in women with menstrual cycle-related IBS. The addition of tibolone does not reduce effectiveness compared with agonist alone and increases QoL.
AB - Objective: To evaluate the effectiveness of gonadotropin-releasing hormone agonists (GnRH-a) with or without coadministration of tibolone in women with menstrual cycle-related irritable bowel syndrome (IBS). Design: Prospective, randomized, placebo-controlled clinical trial. Setting: Universities of Catanzaro and Naples. Patient(s): One hundred twenty young premenopausal women with menstrual cycle-related IBS (Rome II criteria). Intervention(s): Administration of leuprolide acetate depot (LAD, 11.25 mg IM/3 months) plus tibolone (group A), LAD plus placebo tablets (group B), and injection of a placebo solution plus placebo tablets (group C). Main Outcome Measure(s): Severity of bowel symptoms or signs of IBS and quality of life (QoL), at baseline and after 6 months of treatment. Result(s): In all groups, the mean scores for each symptom or sign of IBS and for QoL were significantly improved after treatment. A significant difference was observed between group C and groups A and B. No difference between these last groups was detected in symptoms or signs of IBS. The QoL scores were significantly higher in group A than in group B. Conclusion(s): Gondotropin-releasing hormone agonist administration is effective in women with menstrual cycle-related IBS. The addition of tibolone does not reduce effectiveness compared with agonist alone and increases QoL.
KW - GnRH analogue
KW - Irritable bowel syndrome (IBS)
KW - Menstrual cycle
KW - Quality of life
KW - Sex hormones
UR - http://www.scopus.com/inward/record.url?scp=17044428448&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=17044428448&partnerID=8YFLogxK
U2 - 10.1016/j.fertnstert.2004.12.007
DO - 10.1016/j.fertnstert.2004.12.007
M3 - Article
C2 - 15820814
AN - SCOPUS:17044428448
VL - 83
SP - 1012
EP - 1020
JO - Fertility and Sterility
JF - Fertility and Sterility
SN - 0015-0282
IS - 4
ER -